Revolution Medicines, Inc. (RVMD) Stock Analysis
A live, multi-source view of Revolution Medicines, Inc. (RVMD): real-time price, technical indicators, Wall Street analyst consensus, recent news sentiment and social buzz — aggregated into one place so you can size up the stock at a glance.
About Revolution Medicines, Inc.
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers. Its RAS(ON) inhibitors include daraxonrasib (RMC-6236), elironrasib G12C (RMC-6291) which is in early clinical development for the treatment of solid tumors, and zoldonrasib G12D (RMC-9805), which are in phase 3 registrational trial evaluating the combination of daraxonrasib with zoldonrasib in patients with 1L PDAC; and development candidates comprise RMC-5127 (G12V) which is in clinical trial, RMC-0708 (Q61H), that is in clinical trial; and RMC-8839 (G13C). Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
Sector: Healthcare · Industry: Biotechnology · United States · 883 employees · revmed.com
Key statistics · as of 2026-09-06
As of 2026-09-06, Revolution Medicines, Inc. (RVMD) had a market capitalization of $45.01B (forward -35.9) and a beta of 1.41; the shares traded in a 52-week range of $39.73 – $224.31 (413.6% over the year).
- Market cap
- $45.01B
- Enterprise value
- $42.27B
- Forward P/E
- -35.9
- Price / book
- 28.03
- EPS (trailing)
- $-8.86
- EPS (forward)
- $-5.85
- Payout ratio
- 0.0%
- 52-week range
- $39.73 – $224.31
- 52-week change
- 413.6%
- Beta
- 1.41
- Average volume
- 2.3M
- Shares outstanding
- 214.3M
- Short % of float
- 4.79%
- Profit margin
- 0.0%
Fundamental figures are recorded once every few days, dated above; they are not live and can differ from the interactive tiles.
Last universe scan · 2026-09-11
In RapidTradeView’s 2026-09-11 scan of the US universe, Revolution Medicines, Inc. (RVMD) last closed at $203.35 (the last completed close before that scan).
Technicals at the scan: RSI 48 (neutral territory), price -3.2% versus its 20-day average, 20-day versus 50-day average spread +6.1%, MACD histogram -1.83.
Sentiment inputs: 56% of recent Finnhub-scored headlines read bullish; StockTwits 100% bullish; analyst consensus score 79/100.
Next scheduled company event: in 54 days from the scan date.
Scan values are recorded once per trading day and are not live quotes; the interactive tiles above update in real time.
Smart Money · last 90 days
Members of Congress disclosed 0 buys and 0 sells of RVMD; corporate insiders filed 0 buys and 38 sells (3 distinct filers, latest disclosure 2026-09-10). Filings arrive days to weeks after the trade and are not a live signal. Most active filers: Mark A. Goldsmith (0B/18S), Lorence H. Kim (0B/14S), Jeff Cislini (0B/6S). Who is trading what
RapidTradeView pick record
RVMD has not appeared in the daily picks yet. Full scoreboard
What this page covers
RapidTradeView pulls Revolution Medicines, Inc. (RVMD) data from multiple independent sources and combines it into a single dashboard. Below the summary you’ll find live, interactive tiles for each of the following:
- Price & chart — real-time quote with pre/post-market moves and a line or candlestick chart.
- Technical indicators — RSI, MACD, moving averages, Bollinger Bands, volume and support/resistance, distilled into one overall signal.
- Analyst consensus — the buy/hold/sell breakdown and price targets published by Wall Street analysts.
- News sentiment — recent headlines, each scored for tone so the prevailing narrative is obvious.
- Earnings — current EPS, year-over-year change and the next scheduled earnings date.
- Social buzz — Reddit mention volume and StockTwits sentiment for the retail-trader angle.
How to read the signals
No single indicator tells the whole story. A bullish technical reading paired with a cautious analyst consensus, or strong social buzz against weak earnings, is exactly the kind of tension this view is built to surface. RapidTradeView’s signals are generated by deterministic, statistical models — they describe what the data is doing, they are not personalised recommendations to buy or sell RVMD.
Disclaimer: RapidTradeView is an educational sentiment-aggregation tool, not a licensed financial adviser, broker, or dealer. Nothing here is financial, investment, tax, or legal advice. Markets are risky and you can lose money. Always do your own research and consult a qualified professional before making any investment decision.